Health Trials

Papulopustular Rosacea

3

Review clinical trials related to Papulopustular Rosacea. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)

This Phase 2 study aims to evaluate whether Bruton's tyrosine kinase (BTK) inhibition with remibrutinib can produce a clinically meaningful reduction in inflammatory lesions in adults with moderate-to-severe papulopustular rosacea, while also assessing safety and tolerability of remibrutinib in this indication.

Participants needed: 80
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Jul 13, 2026Locations: 1
Eligibility criteria

Signed informed consent must be obtained prior to participation in the study. [+5]

Presence of more than 2 nodular inflammatory lesions [+7]

Read more
Status: Not yet recruiting

A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)

This Phase 2 study aims to evaluate whether Bruton's tyrosine kinase (BTK) inhibition with remibrutinib can produce a clinically meaningful reduction in inflammatory lesions in adults with moderate-to-severe papulopustular rosacea, while also assessing safety and tolerability of remibrutinib in this indication.

Participants needed: 80
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Jul 2, 2026
Eligibility criteria

Signed informed consent must be obtained prior to participation in the study. [+5]

Presence of more than 2 nodular inflammatory lesions [+7]

Read more
Status: Recruiting

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.

Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Narrows Institute for Biomedical ResearchUpdated: May 6, 2025Locations: 1
Eligibility criteria

Men and women ages 18+. [+4]

Subject has any skin pathology or condition that could interfere with the evalua... [+8]

Read more